Seventure leads €5.8m series-A for appetite researcher TargeDys

The French health research company will use the funds to step up its research process, finance human clinical studies for its products and demonstrate product clinical efficacy.

The fresh capital should also allow TargeDys to join the premises of the Faculty of Medicine and Pharmacy of Rouen and hire additional staff, especially doctors and engineers.

The round, led by European venture capital firm Seventure, also saw investment from Israeli fund Pontifax, which focuses on innovation in the life sciences field; and NCI, a regional fund established by the Conseil Régional de Haute-Normandie.

Company
TargeDys is a startup devoted to research in the modulation of appetite, developing functional food, medical food and pharmaceutical products aimed at regulating appetite.

Its products target high appetite leading to obesity, and low appetite leading to malnourishment in elderly people, cachexia and anorexia.

Its activity is based on research by company founders Serguei Fetissov and Pierre Déchelotte, who have identified and described the first molecular link of the gut-brain axis.

People
Seventure – Isabelle de Crémoux (president, CEO).
Pontifax – Tomer Kariv (CEO).
NCI – Laurie Périé (chargée d'affaires).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• France
• Seventure (SPEF)
• France
• Venture